Big strides in children's healthcare as USask's Dr. Tyler Wenzel is awarded for rethinking treatments for rare pediatric ...
A seven-year Dutch study shows that a single baseline blood measurement of neurofilament light chain predicts the pace of ...
Neuraxpharm and Minoryx have announced that the European Commission has granted marketing authorisation under exceptional ...
Nervonic acid (NA) — a rare fatty acid crucial for brain development and fighting neurodegenerative diseases — is notoriously ...
Neuraxpharm Group and Minoryx Therapeutics, today announce that the European Commission (EC) has granted marketing authorization under exceptional circumstances for NEZGLYAL® (leriglitazone), an ...
On September 21, 2026, the European Commission granted marketing authorization under exceptional circumstances for Nezglyal ...
The therapy is the first approved pharmacological treatment for cALD in the European Union (EU). The approval is based on results from the Phase 2/3 NEXUS1 study and additional real-world evidence ...
Maxxine Dupri recently shared a personal update on social media. She discussed her late brother's battle with adrenoleukodystrophy and her contribution to a nonprofit organization.
Suggested remit: To appraise the clinical and cost effectiveness of leriglitazone within its marketing authorisation for treating adrenoleukodystrophy. The Prioritisation Board agreed that all four of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results